patient with pancytopenia. Bone marrow shows 12% blasts with dysplasia

patient with pancytopenia. Bone marrow shows 12% blasts with dysplasia NGS- attached

Reading File

Loading Image

Finding Sources

Searching PubMed

PTPN11 ASXL1 SF3B1 myelodysplastic syndrome blasts

Finding Sources

Searching PubMed

PTPN11 mutation myelodysplastic syndrome prognosis

Searching PubMed

MDS excess blasts IPSS-M molecular score treatment 2024

Finding Sources

Reading Article

Searching the Web

WHO 2022 MDS classification 10-19% blasts MDS-EB2 PTPN11 ASXL1 SF3B1 IKZF1 molecular prognosis

Now I have comprehensive information to synthesize a full clinical interpretation. Here is the complete analysis:

Clinical Interpretation

Diagnosis

Bone marrow findings: Pancytopenia + 12% blasts + multilineage dysplasia

Under WHO 2022 classification → MDS-IB2 (Myelodysplastic Neoplasm with Increased Blasts, grade 2; blasts 10–19%)

Under ICC 2022 → MDS/AML (the category replacing the old MDS-EB2, covering 10–19% blasts in blood or BM)

Key clinical implication: WHO 2022 notes MDS-IB2 can be treated as AML if clinically indicated. ICC explicitly makes this a borderline MDS/AML entity eligible for both MDS and AML clinical trials.

NGS Mutation Interpretation

Gene	Pathway	Significance
PTPN11	RAS/MAPK signaling (SHP-2 phosphatase)	High-risk: RAS pathway activation; associated with AML progression (HR 1.36, 95% CI 1.01–1.85 for decreased OS in MDS). PTPN11 mutation in MDS carries ~54% AML transformation rate vs ~25% in WT (PMID 39743269). Acts similar to NRAS/KRAS activation.
ASXL1	Epigenetic regulation (Polycomb complex)	High-risk: One of the strongest adverse prognostic mutations in MDS; included in IPSS-M scoring as a high-risk gene. Associated with high-risk MDS, accelerated progression, poor OS.
SF3B1	RNA splicing	Context-dependent: Typically associated with ring sideroblasts and favorable prognosis in lower-risk MDS (MDS-SF3B1 subtype). However, when co-occurring with high blast count (≥5% blasts or increased blasts), its favorable effect is lost — must not be classified as MDS-SF3B1 in this setting.
IKZF1	Transcription factor (lymphoid/myeloid development)	IKZF1 mutations/deletions are classically associated with B-ALL but also occur in myeloid neoplasms; in the myeloid context, confers adverse prognosis and is listed in MDS NGS panels. May suggest lineage plasticity or high genomic instability.

Risk Stratification

IPSS-M (Molecular IPSS) — this case has multiple adverse-risk features:

Blast count (10–19%): Very high-risk category
ASXL1 mutation: Adverse molecular marker
PTPN11 mutation: RAS pathway — adverse (not yet formally incorporated into IPSS-M but established prognostically)
IKZF1 mutation: Adverse
SF3B1: Does not confer favorable effect at this blast count

Overall: Very High Risk / High Risk by IPSS-M

Diagnostic Nuances & Next Steps

Karyotype / FISH — essential to determine if any AML-defining cytogenetic abnormality is present (e.g., del(5q), -7, complex karyotype), which could upstage to AML-MRC (AML with myelodysplasia-related changes)
Ring sideroblast % (Prussian blue stain) — SF3B1 is present; if >5% ring sideroblasts AND blasts were <5%, this would be MDS-SF3B1. At 12% blasts, that classification does not apply — but sideroblast quantification is still useful for documentation.
Check for NPM1, FLT3-ITD, CEBPA — if present with ≥10% blasts, WHO 2022 would reclassify to AML with defining genetic abnormality (no blast % threshold required for those).
Germline PTPN11 — exclude Noonan syndrome–associated JMML (particularly if younger patient; PTPN11 germline causes JMML and Noonan with MDS-like presentations).

Management Implications

Consideration	Recommendation
Age/fitness	If fit: evaluate for allogeneic stem cell transplant (allo-SCT) — only curative option given high-risk molecular profile
Bridge to transplant	Hypomethylating agents (azacitidine or decitabine/cedazuridine) ± venetoclax — standard for high-risk MDS-IB2
Clinical trial	ICC MDS/AML classification enables enrollment in both MDS and AML trials — important given PTPN11/RAS pathway (MEK inhibitors under investigation)
SF3B1 + luspatercept	Not applicable at this blast count despite SF3B1 mutation (luspatercept approved for lower-risk MDS-SF3B1 only)
ASXL1	No direct targeted therapy approved; adverse marker guiding transplant urgency

Summary

This is high-risk MDS-IB2 (WHO 2022) / MDS/AML (ICC 2022) with a molecularly adverse profile driven by ASXL1 + PTPN11 (RAS pathway activation) + IKZF1, where SF3B1 loses its favorable connotation due to the blast excess. PTPN11 is particularly notable — a 2026 meta-analysis (PMID 41804592) confirms RAS pathway mutations (including PTPN11) independently worsen OS in MDS (HR 1.36, P=0.046). Urgent evaluation for allo-SCT is indicated.

Is there a blast % threshold for FLT ITD

Searching the Web

WHO 2022 FLT3-ITD AML blast threshold classification requirement

Yes — FLT3-ITD does have a blast % threshold, and it differs from NPM1.

FLT3-ITD Blast Threshold by Classification System

System	FLT3-ITD Blast Requirement	Notes
WHO 2022	≥10% blasts to call AML	FLT3-ITD is listed among "AML with defining genetic abnormalities" — the ≥20% threshold is eliminated for this group
ICC 2022	≥10% blasts → AML; <10% blasts → not classifiable as AML by FLT3-ITD alone	Same threshold as WHO 2022 for this group
ELN 2022	≥10% blasts to diagnose AML (aligns with ICC)	FLT3-ITD → intermediate risk regardless of allelic ratio
WHO 2022 exception	BCR::ABL1 still needs ≥20%	To avoid overlap with CML accelerated phase

Key Distinction vs NPM1

NPM1 mutation in WHO 2022 eliminates the blast threshold entirely — NPM1-mutated myeloid neoplasm is classified as AML regardless of blast % (even <10% blasts).

FLT3-ITD does NOT have the same "any blast %" status — it still requires ≥10% blasts to establish AML.

So if FLT3-ITD were present in your current patient (12% blasts), it would qualify for AML classification under both WHO 2022 and ICC 2022 — and would confer intermediate ELN risk (or adverse if co-occurring with adverse cytogenetics).

Back to your patient

With 12% blasts:

FLT3-ITD (if present) → AML with FLT3-ITD (≥10% threshold met) → reclassifies from MDS-IB2 to AML, mandating AML-directed therapy (midostaurin or quizartinib-containing induction)
NPM1 (if present) → same outcome (AML regardless of blast%)
CEBPA mutation → still requires ≥20% blasts — so at 12%, CEBPA would not reclassify to AML

reference for >10% blasts

The sources from the previous search already cover this directly. Here are the citable references:

Primary References for ≥10% Blast Threshold (FLT3-ITD → AML)

1. ELN 2022 Recommendations (Döhner et al., Blood 2022)

"All recurrent genetic abnormalities that define specific subtypes of AML, with the exception of AML with BCR::ABL1, are now considered to establish a diagnosis of AML if there are ≥10% blasts in the bone marrow or blood."

Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. PMID: 35797463

2. ICC 2022 (Arber et al., Blood 2022)

ICC mandates a blast cutoff of ≥10% for diagnosing AML with recurrent genetic abnormalities (including FLT3-ITD), except BCR::ABL1 which still requires ≥20%.

Arber DA, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. PMID: 35767897

3. WHO 2022 (Khoury et al., Leukemia 2022)

WHO 5th edition eliminates the ≥20% blast requirement for AML with defining genetic abnormalities (including FLT3-ITD), replacing it effectively with ≥10% in alignment with ICC.

Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematological Tumours. Leukemia. 2022;36(7):1703–1719. PMID: 35732831

All three landmark 2022 classification frameworks are concordant on the ≥10% threshold for FLT3-ITD (and other recurrent genetic abnormalities), with BCR::ABL1 as the sole exception requiring ≥20%.

This is a shared conversation. Sign in to Orris to start your own chat.